Tango Therapeutics Inc

Crystal Adam’s recent Tango Therapeutics insider trades reveal a bullish stance: buying at $5.20, selling at $25, and liquidating options—signal confidence in near‑term valuation and future clinical milestones.

Crystal Adam’s recent sale of 20,251 Tango Therapeutics shares signals routine, pre‑planned trading, not a red flag, as the company’s strong trial data and cash runway keep investor confidence intact.

Crystal Adam’s recent Tango stock sale signals disciplined risk‑management, not panic, as she’s building options for a bullish future. Investors should watch the Q4 earnings to gauge potential upside.

Insider buys show Tango CFO and execs confident in its drug pipeline and rising stock value, but watch earnings and future funding risks.